vTv Therapeutics, Inc. a biopharmaceutical company, reported results that just exceeded analysts’ estimates and updated on two studies in a press release Wednesday.

The company reported an adjusted loss per share of 10 cents for the third quarter, down 1 cent from the second quarter. The figure exceeded analysts’ estimate by 1 cent.

Cash and cash equivalents were $2.4 million at the end of the second quarter compared to $1.5 million on June 30.

The company reported $8,000 in revenue for the third quarter, down from $1.8 million in the second quarter. Analysts estimated third quarter revenue to be $1.68 million, according to Bloomberg data.

vTv said it is actively enrolling patients in its Elevage Study of azeliragon for Alzheimer’s patients with type 2 diabetes. The company expects topline results from phase 2 by late 2020 or early 2021.

The company said it is also fully enrolled for its SimpliciT-1 Study of TTP399 in patients with type 1 diabetes.

“Based on the data we’ve seen to date in our trial of TTP399 in patients with type 1 diabetes, we believe our glucokinase activator could eventually provide a meaningful treatment option to patients with type 1 diabetes that would lower A1c, improve glycemic control and reduce daily insulin use, without increasing hypoglycemic events,” said CEO Steve Holcombe.

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing human therapeutics. Shares of vTv traded at $1.44 on Friday, down 4 cents.